pISSN 2508-6235 eISSN 2508-7576

Download original image
Fig. 2. Changes of cardiac markers before and after treatment with sodium-glucose cotransporter-2 inhibitor (SGLT2i) or dipeptidyl peptidase-4 inhibitor (DPP4i). Changes of blood pressure (BP; systole [A], diastole [B]), N-terminal prohormone of brain natriuretic peptide (NT-pro BNP [C]), ejection fraction (D), and ratio of mitral peak velocity of early filling velocity to early diastolic mitral annular velocity (E/e’ [E]) were significant with SGLT2 inhibitors.
J Obes Metab Syndr 2019;28:254~261 https://doi.org/10.7570/jomes.2019.28.4.254